论文信息 - Discovering translational biomarkers in neurodevelopmental disorders

Discovering translational biomarkers in neurodevelopmental disorders

Investment in drug development for neurodevelopmental disorders has suffered from recent failures in clinical trials that were based on promising preclinical findings. Here, we discuss development and validation of translational biomarkers of neurodevelopmental disorders that can enable more informative clinical experiments and translational success in these diseases.Investment in drug development for neurodevelopmental disorders has suffered from recent failures in clinical trials that were based on promising preclinical findings. Here, we discuss development and validation of translational biomarkers of neurodevelopmental disorders that can enable more informative clinical experiments and translational success in these diseases.

[1] K. Kapur,et al. Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders , 2017, Annals of clinical and translational neurology.

[2] Matthew W. Mosconi,et al. Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome , 2017, Molecular Autism.

[3] M. Fagiolini,et al. Visual evoked potentials detect cortical processing deficits in Rett syndrome , 2015, Annals of neurology.

[4] Mark F. Bear,et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome , 2017, Nature Reviews Drug Discovery.

[5] Guido Gerig,et al. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age , 2017, Science Translational Medicine.